Barr’s BLA for adenovirus oral vaccines accepted for filing by FDA
These oral vaccines represent Barr’s first in-house biologics development initiative and demonstrate the company’s ability to develop, manufacture and conduct clinical trials for biologic products, said Barr. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.